Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 10,000 shares of the business’s stock in a transaction dated Tuesday, June 8th. The shares were sold at an average price of $70.18, for a total value of $701,800.00. Following the completion of the transaction, the insider now directly owns 523,904 shares of the company’s stock, valued at approximately $36,767,582.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Derek J. Maetzold also recently made the following trade(s):
- On Monday, April 26th, Derek J. Maetzold sold 14,374 shares of Castle Biosciences stock. The shares were sold at an average price of $69.17, for a total value of $994,249.58.
Shares of Castle Biosciences stock traded up $0.32 on Thursday, hitting $71.22. The company’s stock had a trading volume of 230,920 shares, compared to its average volume of 289,573. Castle Biosciences, Inc. has a 1 year low of $34.72 and a 1 year high of $107.69. The firm’s fifty day moving average is $63.70. The firm has a market cap of $1.78 billion, a P/E ratio of -99.86 and a beta of 0.42.
A number of large investors have recently bought and sold shares of the business. Principal Financial Group Inc. increased its stake in Castle Biosciences by 13.0% during the 1st quarter. Principal Financial Group Inc. now owns 88,564 shares of the company’s stock worth $6,063,000 after buying an additional 10,212 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Castle Biosciences during the 1st quarter worth approximately $300,000. Voloridge Investment Management LLC increased its stake in Castle Biosciences by 16.1% during the 1st quarter. Voloridge Investment Management LLC now owns 41,070 shares of the company’s stock worth $2,812,000 after buying an additional 5,692 shares in the last quarter. Grandeur Peak Global Advisors LLC increased its stake in Castle Biosciences by 346.1% during the 1st quarter. Grandeur Peak Global Advisors LLC now owns 39,339 shares of the company’s stock worth $2,693,000 after buying an additional 30,520 shares in the last quarter. Finally, Select Equity Group L.P. purchased a new stake in Castle Biosciences during the 1st quarter worth approximately $24,651,000. Institutional investors own 84.99% of the company’s stock.
Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Castle Biosciences from a “sell” rating to a “hold” rating in a report on Monday, May 10th. Robert W. Baird reissued a “buy” rating and issued a $73.00 price objective on shares of Castle Biosciences in a report on Thursday, May 13th. Finally, Lake Street Capital started coverage on Castle Biosciences in a report on Friday, April 30th. They issued a “buy” rating and a $94.00 price objective for the company. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Castle Biosciences currently has a consensus rating of “Buy” and an average price target of $80.29.
About Castle Biosciences
Castle Biosciences, Inc, a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue.
See Also: What is the CAC 40 Index?
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.